AVBP - NASDAQ

ArriVent BioPharma, Inc. Common Stock

AVBP·NASDAQ

$29.78

-0.47%

HealthcareBiotechnology

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.39B

EPS-4.3200

P/E Ratio-6.89

Earnings Date08/10/2026

333.17M

Assets

21%

3Y+82.0%

5Y+674.0%

10Y+674.0%

25.95M

Total Liabilities

50%

3Y+210.0%

5Y+1327.0%

10Y+1327.0%

307.22M

Total Equity

19%

3Y+76.0%

5Y+645.0%

10Y+645.0%

ArriVent BioPharma, Inc. Common Stock Funding & Solvency Profile

AVBP · NASDAQ

Current Assets

Cash & Cash Equivalents45.54M

Net Receivables0.00

Inventory0.00

Other Current Assets20.08M

Total Current Assets333 M

Non-Current Assets

Property, Plant & Equipment13.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets259.00K

Total Non-Current Assets272 K

Total Assets

333.17M

Financial Health Analysis

Current Ratio

12.83x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.08x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

307 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ArriVent BioPharma, Inc. Common Stock Balance Sheet

AVBP • NASDAQ

ArriVent BioPharma, Inc. Common Stock Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	45.5M	74.3M	150.4M	163.4M	37.3M
Short-Term Investments	267.3M	144.6M	0.0	0.0	0.0
Cash & Short-Term Investments	312.8M	218.9M	150.4M	163.4M	37.3M
Net Receivables	0.0	500K	0.0	0.0	0.0
Accounts Receivables	0.0	500K	0.0	0.0	0.0
Prepaids	0.0	7.6M	368K	333K	29K
Other Current Assets	20.1M	0.0	9.2M	18.9M	5.6M
Total Current Assets	332.9M	227M	160M	182.6M	43M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	13K	154K	291K	139K	0.0
Long-Term Investments	0.0	47.7M	0.0	0.0	0.0
Other Non-Current Assets	259K	126K	2.8M	72K	87K
Total Non-Current Assets	272K	48M	3.1M	211K	87K
Total Assets	333.2M	274.9M	163.1M	182.8M	43M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.9M	3.8M	4.5M	3.1M	293K
Accounts Payable	5.9M	3.8M	4.5M	3.1M	293K
Accrued Expenses	0.0	9.2M	7M	5.1M	1.5M
Short Term Debt	14K	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	162K	140K	128K	0.0
Other Current Liabilities	20M	4.2M	0.0	0.0	0.0
Total Current Liabilities	25.9M	17.3M	11.6M	8.4M	1.8M
NON-CURRENT LIABILITIES
Total Non-Current Liabilities	0.0	14K	177K	11K	0.0
Capital Lease Obligations	0.0	176K	317K	139K	0.0
Total Liabilities	25.9M	17.3M	11.8M	8.4M	1.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	304.5M	259.6M	89.9M
Common Stock	4K	3K	0.0	0.0	0.0
Additional Paid-In Capital	711.8M	496.2M	4.7M	3.4M	3M
Retained Earnings	-404.6M	-238.3M	-157.8M	-88.5M	-51.6M
Accumulated Other Comprehensive Income/Loss	14K	-211K	0.0	0.0	-2K
Total Stockholders' Equity	307.2M	257.7M	151.3M	174.5M	41.2M
Total Equity	307.2M	257.7M	151.3M	174.5M	41.2M
SUMMARY
Total Liabilities & Equity	333.2M	274.9M	163.1M	182.8M	43M
Total Investments	267.3M	192.3M	0.0	0.0	0.0
Total Debt	14K	176K	317K	139K	0.0
Net Debt	-45.5M	-74.1M	-150.1M	-163.2M	-37.3M
Shares Outstanding	40,568,943	40,568,943	40,568,943	40,568,943	40,568,943

SEC Filings

AVBP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 10, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 09, 2025	September 09, 2025	2025	View Filing

Showing 1 to 10 of 42 filings

Related Guides

Blog Categories

Continue your AVBP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.